These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Dopamine agonists as primary treatment in Parkinson's disease. Rinne UK Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394 [No Abstract] [Full Text] [Related]
24. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. Hironishi M; Miwa H; Kondo T No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758 [TBL] [Abstract][Full Text] [Related]
25. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Rascol O Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400 [No Abstract] [Full Text] [Related]
26. What has been learnt from study of dopamine receptors in Parkinson's disease? Hurley MJ; Jenner P Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973 [TBL] [Abstract][Full Text] [Related]
27. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141 [TBL] [Abstract][Full Text] [Related]
28. Controversies in the treatment of Parkinson's disease. Friedman J R I Med J (1976); 1985 Oct; 68(10):461-3. PubMed ID: 3865336 [No Abstract] [Full Text] [Related]
30. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)]. Meco G; Casacchia M; Zamponi A; Agnoli A Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900 [No Abstract] [Full Text] [Related]
31. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa. Gawel M; Riopelle R; Libman I; Bouchard S Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263 [No Abstract] [Full Text] [Related]
32. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment. Zimmerman TR; Sage JI; Lang AE; Mark MH Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678 [TBL] [Abstract][Full Text] [Related]
33. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment. Caraceni TA; Girotti F; Giovannini P; Parati E J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210 [TBL] [Abstract][Full Text] [Related]
34. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Brusa L; Petta F; Pisani A; Moschella V; Iani C; Stanzione P; Miano R; Finazzi-Agrò E Neurology; 2007 May; 68(18):1455-9. PubMed ID: 17470746 [TBL] [Abstract][Full Text] [Related]
35. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats. Rose S; Jenner P; Marsden CD Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899 [TBL] [Abstract][Full Text] [Related]
36. Treatment of Parkinson's disease: levodopa as the first choice. Katzenschlager R; Lees AJ J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059 [TBL] [Abstract][Full Text] [Related]
37. New perspectives in the treatment of Parkinson's disease. LeWitt PA Clin Neuropharmacol; 1986; 9 Suppl 1():S37-54. PubMed ID: 3085929 [No Abstract] [Full Text] [Related]